In a nutshell
This study looked at the use of blood markers to measure treatment activity of L-asparaginase in acute lymphoblastic leukemia (ALL). Researchers found that antithrombin (AT) and fibrinogen (FIB) could be used to measure effective levels of L-asparaginase in these patients.
Some background
L-asparaginase is a treatment for acute lymphoblastic leukemia (ALL). It is obtained from a bacteria called E. coli. This may lead to allergic reactions which may reduce effectiveness. Antithrombin (AT) and fibrinogen (FIB) are blood markers involved in clotting. It is not known if these markers may be used to measure treatment activity of L-asparaginase.
Methods & findings
97 patients with ALL treated with L-asparaginase were included in this study. Blood markers such as AT, FIB, and other proteins were measured. L-asparaginase activity was also measured.
A higher activity of AT, FIB and protein levels was linked with lower effective levels of L-asparaginase in these patients.
The bottom line
The study concluded that AT combined with FIB may be good markers of L-asparaginase activity in patients with ALL.
The fine print
This study had a small sample size. Larger studies may be needed to confirm results.
Published By :
Pediatric blood & cancer
Date :
Apr 02, 2019
